The proposed invention enables the detection of fluorescently labeled circulating cells directly in the blood stream without having to draw blood samples. The primary use is to study the metastatic progression (spread via the bloodstream) of cancer in model animal systems, and potentially in humans. Target cells must be fluorescently labeled, either by use of fluorescence dyes, fluorescent proteins, or antibody-targeted fluorescent molecular probes.
Technology Overview
The design consists of a novel computational engine (computer software) that requires that moving cells be detected on all (2 or more) light detectors before a detection event. The software analyzes properties of the detected signal from a cell (for example, amplitude, width, speed) and then combines them, and requires that cell signals be detected on all or more than one detector. This allows determining the speed and blood vessel of travel, and significantly reduces false detection events due to movements and electronic noise.
The main advantage is that the system allows for the detection of circulating tumor cells or circulating tumor cell clusters at concentrations as low as 1 cell per mL of circulating blood. This is orders of magnitude improved sensitivity versus existing technologies.
- Higher sensitivity than existing technologies
- Can be used for longer limb species, potentially humans
- Software mitigates false detections
- Immuno‑oncology
- Oncology
- Imaging
- Biomedical devices
- Diagnostics
- License
- Partnering
- Research Collaboration
Patent Information:
1. Life Science
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
Mark Niedre